Daiichi Sankyo Company, Limited
Daiichi Sankyo Company, Limited Financial Summary for the Six Months Ended March 2027 (IFRS, Consolidated)
Interim revenue was 1,167,233 million yen, up 19.7% year-over-year. Core operating profit was 221,331 million yen, up 46.9%; operating profit was 193,795 million yen; interim profit was 151,534 million yen. For fiscal 2027 the dividend policy anticipates a full-year dividend of 100 yen including a 50 yen interim dividend. Supplementary earnings materials are available and an earnings presentation will be held.
Key Figures
- Revenue: 1,167,233 million yen (Year-over-Year +19.7%)
- Core Operating Profit: 221,331 million yen (Year-over-Year +46.9%)
- Operating Profit: 193,795 million yen (Year-over-Year +34.4%)
AI要約
Business Performance Overview
For the interim period, consolidated revenue was 1,167,233 million yen (Year-over-Year +19.7%), core operating profit was 221,331 million yen (+46.9%), and operating profit was 193,795 million yen (+34.4%). Currency effects and growth across product portfolios contributed to the results. By segment, the oncology business made a major contribution, and other units including EU Specialty and ASCA also performed solidly. Research and development expenditures expanded. Supplementary earnings materials and an earnings presentation are provided.
Shareholder Returns and Financial Position
Cash and cash equivalents increased at the interim period end; total assets were 4,258,600 million yen, and some treasury shares have been cancelled. The full-year dividend for fiscal 2026 is planned at 100 yen, with an interim dividend of 50 yen to be paid. Results of treasury share cancellations are reported, and the shareholder return policy as part of capital policy is being continued.
Revenue Trend
Core Operating Profit Trend
Margin Trend
Segment Revenue Breakdown
Full-Year Guidance vs Actual Comparison
Daiichi Sankyo Company, Limited
Company overview · Stock price · Financial data · All IR
